Jeff Vierstra, a 41-year-old scientist and skier, is facing the legacy of Amyotrophic Lateral Sclerosis (ALS) head-on. With a family history marked by the disease, he has experienced profound loss; his mother died from ALS when he was just two years old, and both of his sisters succumbed to complications associated with the same condition. However, Vierstra remains hopeful as he participates in an experimental treatment aimed at preventing the onset of ALS in those genetically predisposed to develop it.
### Family Legacy of ALS
ALS, commonly referred to as Lou Gehrig’s disease, causes the progressive degeneration of motor neurons, which control muscle movement. Affected individuals may ultimately lose the ability to walk, talk, or even breathe. About 10% to 15% of all ALS patients possess a genetic form of the disease, with familial cases—that is, those that run in families—making up around two-thirds of those instances. Dr. Neil Shneider, a neurologist at Columbia University, is conducting groundbreaking research into these genetic forms.
Vierstra, along with his sisters Erin and Leigh, has tested positive for a mutation in the FUS gene, which is essential for the proper functioning of nerve cells. The existence of this mutation places them at a heightened risk for developing ALS. Reflecting on this daunting reality, Vierstra remarked, “Living with that sort of cloud over you is like mentally and emotionally really difficult.”
### Experimental Treatment
In light of this family medical history, both sisters began to exhibit symptoms of ALS and subsequently participated in a clinical trial for a targeted experimental treatment at Columbia University. When Dr. Shneider reviewed Vierstra’s health data, he identified abnormalities in muscle electrical signals, indicating an early risk of disease onset. During this harrowing evaluation, Dr. Shneider informed Vierstra that he might also be facing a similar fate.
Determined to take proactive measures, Vierstra eagerly accepted the opportunity to join his sisters in the clinical trial. For the past three years, he has been receiving infusions targeting the mutated gene through his spine, a treatment designed to disrupt the progression of ALS. Despite his sisters eventually developing severe complications and passing away, Vierstra believes the treatment may have prolonged their lives.
After one year of treatment, promising signs emerged; the previously mild abnormalities noted during his muscle assessments had normalized. Crucially, Vierstra has not yet developed ALS and is currently outliving many family members who succumbed to the disease.
### Hope for the Future
Dr. Shneider believes that this research could be transformative not only for those affected by familial ALS but also for individuals with sporadic forms of the disease. He expressed optimism, stating, “I think there’s real hope and opportunity to make this a livable disease, one that isn’t fatal.”
Despite the challenges he faces, Vierstra continues to excel in his professional life and maintain an active lifestyle, including skiing, hiking, and traveling. This participation in the treatment has revitalized his outlook on the future, allowing him to envision a life that once felt uncertain. In his own words, “And maybe this actually is working for me, and I can start thinking about the future, and I otherwise couldn’t have.”
### Ongoing Research and Community Involvement
The ALS Center at Columbia University is not only focused on FUS-related ALS but also aims to expand its research to include other rare genetic forms of the disease. The team is working to develop individualized gene-based therapies through its initiative known as “Silence ALS.” The goal is to make HLS more manageable for all patients.
Individuals interested in potential participation in this initiative can reach out to the ALS Center at silenceals@cumc.columbia.edu.
As research in the field continues to progress, those like Jeff Vierstra remain at the forefront, embodying both the challenges of familial disease and the infinite possibilities offered through modern science. With supportive care and research, there is a tangible hope for a future where ALS is no longer a death sentence but rather a manageable condition.
Source: Original Reporting
About The Author
